(19)
(11) EP 2 155 683 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.09.2011 Bulletin 2011/38

(45) Mention of the grant of the patent:
16.03.2011 Bulletin 2011/11

(21) Application number: 08752572.1

(22) Date of filing: 02.05.2008
(51) International Patent Classification (IPC): 
C07D 213/82(2006.01)
C07D 413/12(2006.01)
A61P 29/00(2006.01)
 C07D 401/12(2006.01)
A61K 31/4412(2006.01)
(86) International application number:
PCT/JP2008/058689
(87) International publication number:
WO 2008/140066 (20.11.2008 Gazette 2008/47)

(54)

PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS

PYRIDONDERIVATE ALS INHIBITOREN VON P38A-MAPK

DÉRIVÉS DE PYRIDONE EN TANT QUE INHIBITEURS DE P38A MAPK

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 03.05.2007 US 915845 P

(43) Date of publication of application:
24.02.2010 Bulletin 2010/08

(73) Proprietors:
  • Astellas Pharma Inc.
    Tokyo 103-8411 (JP)
  • Wakunaga Pharmaceutical Co., Ltd.
    Osaka-shi Osaka 532-0003 (JP)

(72) Inventors:
  • KASAHARA, Chiyoshi
    Tokyo 103-8411 (JP)
  • YAMAZAKI, Hitoshi
    Tokyo 103-8411 (JP)

(74) Representative: Gille Hrabal Struck Neidlein Prop Roos 
Patentanwälte Brucknerstrasse 20
40593 Düsseldorf
40593 Düsseldorf (DE)


(56) References cited: : 
WO-A-00/07980
WO-A-2006/122154
 WO-A-2006/051826
WO-A-2007/026950
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).